Company news
Innocare Pharma Ltd. Class A (SSE:688428) news
Every Innocare Pharma Ltd. Class A press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
"INNOCARE PHARMA LIMITED"Announcement on Vesting Results for the First Vesting Period of the Reserved Grant under the 2024 STAR Market Restricted Share Incentive Plan and Listing of Shares
September 14, 2026
InnoCare Announces Approval of Clinical Trial of Novel Bispecific ADC ICP-B381 Targeting PSMA/ STEAP1 in China
September 7, 2026
"INNOCARE PHARMA LIMITED"Announcement on the Progress of Acquisition of the Remaining Equity in a Controlled Subsidiary
September 7, 2026
"INNOCARE PHARMA LIMITED"Announcement on the Satisfaction of Vesting Conditions for the First Vesting Period of the Reserved Grant under the 2024 STAR Market Restricted Share Incentive Plan
August 25, 2026
InnoCare Reports 2026 Interim Results, Sustained Profitability and Key Milestones Achieved
August 24, 2026
InnoCare Announces Approval of Head-to-Head Registrational Phase III Trial of Mesutoclax with Azacitidine versus Venetoclax with Azacitidine in Treatment-Naive AML in China
August 17, 2026
InnoCare Announces Orelabrutinib in Combination with Mesutoclax Granted Breakthrough Therapy Designation in China
August 2, 2026
InnoCare's TYK2 Inhibitor Fadeucravacitinib (ICP-488) Meets Primary Endpoint in Phase III Psoriasis Study
July 27, 2026
"INNOCARE PHARMA LIMITED"Announcement on Results of Shareholding Reduction by Directors and Senior Management Members
July 20, 2026
"INNOCARE PHARMA LIMITED"Announcement on Voluntary Disclosure of Soficitinib (ICP-332) Achieving the Primary Endpoint in a Phase II Study for the Treatment of Non-segmental Vitiligo
July 16, 2026
InnoCare Announces Phase III Study Results of TYK2 Inhibitor Soficitinib Meet Primary Endpoint in Patients with Atomic Dermatitis
July 15, 2026
InnoCare Announces Publication in STTT (IF=81.2) of Phase 3 Results Showing Orelabrutinib Significantly Prolonged Progression-Free Survival in Treatment-Naïve CLL/SLL
July 14, 2026
Study Results of Orelabrutinib in Patients with SLE Published in the Journal of Autoimmunity
July 10, 2026
InnoCare Announces First Patient Dosed in Clinical Trial of Novel CDH17 targeted ADC ICP-B208 in China
July 4, 2026
Announcement on Shareholding Reduction Plan for Directors and Senior Management Members
June 24, 2026
Announcement on Vesting Results of the 1st Vesting Period of Those Initially Granted in 2024 STAR Market Restricted Stock Incentive Plan and Listing of Shares
June 23, 2026
Self-Inspection Report on the Trading of Company's Stock by Information Insiders in 2026 STAR Market Restricted Stock Incentive Plan
June 16, 2026
2026 EHA | Over 40 Orelabrutinib Studies Presented, Including First Clinical Data from Europe and US TN CLL/SLL Patients
June 15, 2026
Publicity Explanation and Verification Opinions of the Remuneration Committee of the Board of Directors on List of Initially Granted Incentive Objects in the 2026 STAR Market Restricted Stock Incentive Plan
June 9, 2026
Phase IIb Study Results of InnoCare’s Orelabrutinib in Patients with SLE Presented at 2026 EULAR
June 5, 2026
ASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released
June 1, 2026
InnoCare Announces the Acceptance of New Drug Application for Orelabrutinib in Primary Immune Thrombocytopenia in China
May 28, 2026
Announcement on Voluntary Disclosure of Approval by the Therapeutic Goods Administration of Australia for the Marketing of Orelabrutinib
May 27, 2026
Announcement on Resolutions of the Board of Directors
May 25, 2026
2026 ASCO | Pivotal Data of InnoCare's Novel BCL2 Inhibitor Mesutoclax Released
May 22, 2026
InnoCare Announce First Subject Dosed in Phase 1 Clinical Trial of ICP-054, a Novel Potentially Best-in-Class Oral IL-17AA/AF Inhibitor
May 13, 2026
InnoCare Announces Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Sjögren's Syndrome in China
May 6, 2026
InnoCare Announces Approval of Clinical Trial of Novel CDH7 targeted ADC ICP-B208 in China
May 5, 2026
Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale
April 30, 2026
InnoCare Announces First Patient Dosed in Phase III Trial of Orelabrutinib for SLE
April 27, 2026
Notice on Convening the 2026 Annual General Meeting
April 24, 2026
InnoCare Releases 2026 Q1 Results: Strong Revenue Growth and Sustained Profitability
April 23, 2026
Preclinical Data of Novel B7-H3 ADC ICP-B794 Unveiled at 2026 AACR, Demonstrating Superior Anti-Tumor Activity and Safety
April 21, 2026
Announcement on Convening the Q1 2026 Performance Briefing
April 15, 2026
InnoCare Releases 2025 Results and Business Highlights, Achieving First Annual Profit
March 25, 2026
Announcement on Convening the 2025 Annual Performance Briefing
March 17, 2026
InnoCare Announces First Healthy Volunteer Dosed in Clinical Trial of Novel VAV1 Degrader ICP-538 in China
March 14, 2026
InnoCare’s next-generation TRKi Zurletrectinib Receives Priority Review for the Treatment of Pediatric Patients with Solid Tumors in China
February 28, 2026
InnoCare Announces Key Developments of Critical Clinical Studies
February 25, 2026
InnoCare Announces First Patient Dosed in the Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China
February 11, 2026
InnoCare Announces IND Approval to Initiate Clinical Trial of VAV1 Degrader ICP-538 in China
February 7, 2026
Study Results of Novel TYK2 Inhibitor Soficitinib in Patients with AD Published by JAMA Dermatology
January 29, 2026
InnoCare Announces NMPA Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Cutaneous Lupus Erythematosus
December 23, 2025
InnoCare Announces Approval of Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China
December 16, 2025
Zenas BioPharma’s Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus
December 15, 2025
InnoCare Announces Achievement of Primary Endpoint in Phase IIb Study of Orelabrutinib for SLE and Approval of Phase III Clinical Trial
December 14, 2025
InnoCare Announces Approval of the Next-Generation TRK Inhibitor Zurletrectinib in China
December 11, 2025
Over 20 Studies of InnoCare’s Orelabrutinib Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)
December 8, 2025
Latest Data of InnoCare’s Novel BCL2 Inhibitor Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)
December 7, 2025
InnoCare Announces First Patient Dosed in the Global Phase II Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Prurigo Nodularis
November 26, 2025